PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer

Journal of Nuclear Medicine

Volumn 56, Issue 4, 2015, Pages 616-621

  Jacobson, Orit ^a   Yan, Xuefeng ^a,b   Niu, Gang ^a   Weiss, Ido D ^c   Ma, Ying ^a   Szajek, Lawrence P ^d   Shen, Baozhong ^b   Kiesewetter, Dale O ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

DNA aptamer; PET; Tenascin C

Indexed keywords

APTAMER; COPPER 64; FLUORINE 18; FLUOROBENZOYL APTAMER F 18; NOTA APTAMER CU 64; RADIOPHARMACEUTICAL AGENT; SINGLE STRANDED DNA; TENASCIN; UNCLASSIFIED DRUG; COPPER; FLUORINE; NUCLEOTIDE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE QUALITY; ISOTOPE LABELING; MOUSE; NEOPLASM; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; CONFORMATION; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; FLUORESCENCE MICROSCOPY; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; COPPER RADIOISOTOPES; DIAGNOSTIC IMAGING; DNA, SINGLE-STRANDED; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NUCLEIC ACID CONFORMATION; NUCLEOTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; TENASCIN;

EID: 84928239978     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.149484     Document Type: Article

References (27)

1. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell. 1986;47:131-139.
2. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol. 2003;200:488-499.
3. Tanaka R, Seki Y, Saito Y, et al. Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and PDGF-dependent cell proliferation through potentiated and sustained activation of integrin a5b1. J Biol Chem. 2014;289:17699-17708.
4. Tastekin D, Tas F, Karabulut S, et al. Clinical significance of serum tenascin-C levels in breast cancer. Tumour Biol. 2014;35:6619-6625.
5. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68:3175-3199.
6. Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3:287-310.
7. Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17:867-874.
8. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244:143-163.
9. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer. 2003;98:2430-2439.
10. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 2005;37:1066-1083.
11. Rolle K, Nowak S, Wyszko E, et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther. 2010;9:396-406.
12. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008; 49:30-38.
13. 131I-antitenascin monoclonal antibody 81C6 to deliver a 44-Gy resection cavity boost. Neurooncol. 2008;10:182-189.
14. 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:867-877.
15. Schmidt KS, Borkowski S, Kurreck J, et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 2004;32:5757-5765.
16. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006;47:668-678.
17. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011;18:4206-4214.
18. Tan W, Donovan MJ, Jiang J. Aptamers from cell-based selection for bioanalytical applications. Chem Rev. 2013;113:2842-2862.
19. Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem. 2009;10: 862-868.
20. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA. 2003;100:15416-15421.
21. Reuter JS, Mathews DH. RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics. 2010;11:129-138.
22. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
23. 18F-T140. J Nucl Med. 2010;51:1796-1804.
24. Heuveling DA, de Bree R, Vugts DJ, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54:397-401.
25. 2 in human breast cancer xenograft model. J Nucl Med. 2014;55:1692-1698.
26. Muralidharan V, Nguyen L, Banting J, Christophi C. The prognostic significance of lymphatics in colorectal liver metastases. HPB Surg. 2014;2014: 954604.
27. Akgül Ö, Cetinkaya E, Ersoz S, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20:6113-6122.